Grace Therapeutics GRCE
NASDAQ GRCE
$1.92 -0.05 (-2.28%)
As of: Oct 22, 2026 · 12:08 PM EDT

Grace Therapeutics (GRCE) Cash & Equivalents (2017 - 2026)

Updated

Grace Therapeutics (GRCE) recorded Cash & Equivalents of $13.76 million in fiscal Q1 2027 (quarter ended Jun 30, 2026), up 617.2% from $1.92 million a year earlier but down 19.0% from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Cash & Equivalents (2017 - 2026) Analysis & Trends

At the end of FY2026 (ended Mar 31, 2026), Grace Therapeutics reported Cash & Equivalents of $16.98 million, down 23.3% from FY2025.

  • Annual Cash & Equivalents has declined for five straight fiscal years, with a five-year compound annual growth rate of -19.7% (FY2021 to FY2026).
  • Across earlier fiscal years, Cash & Equivalents came in at $22.13 million in FY2025 (-3.8%), $23.01 million in FY2024 (-17.5%), $27.88 million in FY2023 (-8.1%) and $30.34 million in FY2022 (-40.4%).
  • Quarterly Cash & Equivalents has ranged from $1.92 million in fiscal Q1 2026 to $38.38 million in fiscal Q1 2023 over the past five years.
  • On a year-over-year basis, Cash & Equivalents rose in three of the last eight quarters, with growth averaging 62.0%.
  • Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 617.2% in fiscal Q1 2027, against a decline of 90.1% in fiscal Q1 2026 at the low end.
  • Per Business Quant, the preceding three fiscal quarters came in at $16.98 million (Q4 2026), $18.67 million (Q3 2026) and $16.86 million (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,170.99 Bn 1,139.58 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 642.25 Bn 560.77 Bn 17.26 Bn 20.42 Bn
3 AbbVie 502.08 Bn 475.19 Bn 12.70 Bn 6.57 Bn
4 Merck 375.61 Bn 329.99 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 302.76 Bn 266.75 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 268.66 Bn 242.35 Bn 12.86 Bn 4.90 Bn
7 Amgen 241.98 Bn 197.38 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 193.37 Bn 167.57 Bn 6.22 Bn 3.18 Bn
9 Pfizer 172.42 Bn 119.07 Bn 10.94 Bn 976.00 Mn
10 Grace Therapeutics 33.24 Mn -33.02 Mn - 13.76 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 13.76 Mn
Mar 31, 2026 16.98 Mn
Dec 31, 2025 18.67 Mn
Sep 30, 2025 16.86 Mn
Jun 30, 2025 1.92 Mn
Mar 31, 2025 22.13 Mn
Dec 31, 2024 11.06 Mn
Sep 30, 2024 15.16 Mn
Jun 30, 2024 19.39 Mn
Mar 31, 2024 23.01 Mn
Dec 31, 2023 18.55 Mn
Sep 30, 2023 26.99 Mn
Jun 30, 2023 21.63 Mn
Mar 31, 2023 27.88 Mn
Dec 31, 2022 26.24 Mn
Sep 30, 2022 34.93 Mn
Jun 30, 2022 38.38 Mn
Mar 31, 2022 30.34 Mn
Dec 31, 2021 33.01 Mn
Sep 30, 2021 36.93 Mn
API Access

Grace Therapeutics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GRCE&period=max&api_key=YOUR_API_KEY